July 2014
PUBLICATIONS - Back

Oncology Archives

1. Cui Y, Hausheer F, Beaty R, Zahnow C, Issa JP, Bunz F, Baylin SB. A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Res. 2014 May 29. pii: canres.2287.2013. [Epub ahead of print]
Key words: hypermethylated, recombinant, reactivation
http://www.ncbi.nlm.nih.gov/pubmed/24876104

2. Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendazibal A, Fuchs EJ. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014 May 23. pii: S1083-8791(14)00313-9. doi: 10.1016/j.bbmt.2014.05.015. [Epub ahead of print] Review.
Key words: allogeneic, heamatologic, donor, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/24862638

3. Forde PM, Cochran RL, Boikos SA, Zabransky DJ, Beaver JA, Meyer CF, Thornton KA, Montgomery EA, Lidor AO, Donehower RC, Park BH. Familial GI stromal tumor with loss of heterozygosity and amplification of mutant KIT. J Clin Oncol. 2014 May 27. pii: JCO.2013.51.6633. [Epub ahead of print]
Key words: KIT, mutant, stromal, tumor
http://www.ncbi.nlm.nih.gov/pubmed/24868028

4. Gladstone DE, Davis-Sproul J, Campian J, Lemas MV, Malatyali S, Borrello I, King K, Grossman SA. Infusion of cryopreserved autologous lymphocytes using a standard peripheral i.v. catheter. Bone Marrow Transplant. 2014 May 19. doi: 10.1038/bmt.2014.98. [Epub ahead of print]
Key words: lymphocytes, catheter, cryopreserved
http://www.ncbi.nlm.nih.gov/pubmed/24842526

5. Guo H, Ma O, Friedman AD. The Cebpa +37-kb enhancer directs transgene expression to myeloid progenitors and to long-term hematopoietic stem cells. J Leukoc Biol. 2014 May 27. pii: jlb.2AB0314-145R. [Epub ahead of print]
Key words: transgene, enhancer, hematopoietic
http://www.ncbi.nlm.nih.gov/pubmed/24868087

6. Kuderer NM, Wolff AC. Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol. 2014 May 27. pii: JCO.2014.55.1903. [Epub ahead of print]
Key words: toxicity, options, decision
http://www.ncbi.nlm.nih.gov/pubmed/24868027

7. Lutz ER, Jaffee EM. Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy? Cancer Immunol Res. 2014 Jun;2(6):518-21. doi: 10.1158/2326-6066.CIR-14-0041.
Key words: neoepitopes, vaccine, mutant
http://www.ncbi.nlm.nih.gov/pubmed/24795140

1. Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 1;74(5):1338-48. doi: 10.1158/0008-5472.CAN-13-2357-T. Epub 2014 Jan 21.
Key words: breast tumor, diversity, genetic
http://www.ncbi.nlm.nih.gov/pubmed/24448237

2. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM. A listeria vaccine and depletion of T-regulatory cells activate immunity against early-stage pancreatic intra-epithelial neoplasms and prolong survival of mice. Gastroenterology. 2014 Mar 6. pii: S0016-5085(14)00298-4. doi: 10.1053/j.gastro.2014.02.055. [Epub ahead of print]
Key words: listeria, neoplasms, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/24607504

3. Kern SE, Sitzmann JV. Microvascular architecture in a case of gastric antral vascular ectasia (watermelon stomach). Am J Gastroenterol. 2014 Mar;109(3):449-51. doi: 10.1038/ajg.2013.449.
Key words: antral, watermelon, ectasia
http://www.ncbi.nlm.nih.gov/pubmed/24594964

4. Rucki AA, Zheng L. Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World J Gastroenterol. 2014 Mar 7;20(9):2237-2246. Review.
Key words: pancreatic cancer, stroma
http://www.ncbi.nlm.nih.gov/pubmed/24605023

5. Zabransky DJ, Park BH. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. J Clin Oncol. 2014 Apr 1;32(10):1084-6. doi: 10.1200/JCO.2013.53.5070. Epub 2014 Mar 3.
Key words: tyrosine, breast cancer, epidermal
http://www.ncbi.nlm.nih.gov/pubmed/24590645

1. Cooke KR. A "window of opportunity" for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Jan 25. pii: S1083-8791(14)00024-X. doi: 10.1016/j.bbmt.2014.01.008. [Epub ahead of print]
Key words: Allogeneic, dysfunction, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/24472717
Beumer JH, Venkataramanan R, Rudek MA. Pharmacotherapy in cancer patients with HIV/AIDS. Clin Pharmacol Ther. 2014 Jan 17. doi: 10.1038/clpt.2014.10. [Epub ahead of print]
Key words: HIV, pharmacotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24440966

2. Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res. 2014 Jan 27. [Epub ahead of print]
Key words: immunotherapy, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/24470514

3. Joshu CE, Tsilidis KK, Peskoe SB, Giardiello FM, Dluzniewski PJ, Nelson WG, Iacobuzio-Donahue CA, Platz EA. The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes Control. 2014 Jan 17. [Epub ahead of print]
Key words: colonic, C-reative, inflammation
http://www.ncbi.nlm.nih.gov/pubmed/24435936

4. Kanarek NF, Hooker CM, Mathieu L, Tsai HL, Rudin CM, Herman JG, Brock MV. Survival after community diagnosis of early stage non-small cell lung cancer. Am J Med. 2014 Jan 28. pii: S0002-9343(14)00073-4. doi: 10.1016/j.amjmed.2013.12.023. [Epub ahead of print]
Key words: lung cancer, survival, diagnosis
http://www.ncbi.nlm.nih.gov/pubmed/24486286

5. Park TS, Bhutto I, Zimmerlin L, Huo JS, Nagaria P, Miller D, Rufaihah AJ, Talbot C, Aguilar J, Grebe R, Merges C, Reijo-Pera R, Feldman RA, Rassool F, Cooke J, Lutty G, Zambidis ET. Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation. 2014 Jan 21;129(3):359-72. doi: 10.1161/CIRCULATIONAHA.113.003000. Epub 2013 Oct 25.
Key words: retinal, stem cell, pluripotent, vasculature
http://www.ncbi.nlm.nih.gov/pubmed/24163065

6. Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014 Jan 28. doi: 10.1002/cncr.28554. [Epub ahead of print]
Key words: immunodeficienvy, sunitinib, antiretroviral
http://www.ncbi.nlm.nih.gov/pubmed/24474568

7. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev. 2014 Jan 30. [Epub ahead of print]
Key words: prostate cancer, future, challenges
http://www.ncbi.nlm.nih.gov/pubmed/24477411

8. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014 Jan 24. pii: S0302-2838(14)00069-4. doi: 10.1016/j.eururo.2014.01.018. [Epub ahead of print]
Key words: Abiraterone, docetaxel, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/24491307

9. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey P, Chung CH, Califano JA. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014 Jan 29. [Epub ahead of print]
Key words: NOTCH, activation, pathway
http://www.ncbi.nlm.nih.gov/pubmed/24351288

10. Sur S, Fries AC, Kinzler KW, Zhou S, Vogelstein B. Remote loading of preencapsulated drugs into stealth liposomes. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2283-8. doi: 10.1073/pnas.1324135111. Epub 2014 Jan 28.
Key words: liposomes, preencapsulated, stealth
http://www.ncbi.nlm.nih.gov/pubmed/24474802

11. Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014 Jan 30;123(5):725-33. doi: 10.1182/blood-2013-08-524025. Epub 2013 Dec 17.
Key words: myeloma, factor 15
http://www.ncbi.nlm.nih.gov/pubmed/24345755

1. Bailey E, Li L, Duffield AS, Ma HS, Huso DL, Small D. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21113-8. doi: 10.1073/pnas.1310559110.
Key words: aggressive, ITD, FLT3, mutation
http://www.ncbi.nlm.nih.gov/pubmed/24255108

2. Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA Jr, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. Am J Clin Oncol. 2013 Dec 17. [Epub ahead of print]
Key words: pancreatic cancer, induction, survival
http://www.ncbi.nlm.nih.gov/pubmed/24351782

3. Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC. Treatment of HER2-positive breast cancer. Breast. 2013 Dec 18. pii: S0960-9776(13)00300-7. doi: 10.1016/j.breast.2013.11.011. [Epub ahead of print]
Key words: breast cancer, HER2, treatment
http://www.ncbi.nlm.nih.gov/pubmed/24360619

4. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey P, Chung CH, Califano JA. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014 Jan 29. [Epub ahead of print].
Key words: NOTCH, head and neck cancer, activation

http://www.ncbi.nlm.nih.gov/pubmed/24351288

5. Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W. Growth Differentiating Factor 15 enhances the tumor initiating and self-renewal potential of multiple myeloma cells. Blood. 2013 Dec 17. [Epub ahead of print]
Key words: factor 15, multiple myeloma
http://www.ncbi.nlm.nih.gov/pubmed/24345755

1. Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle O, Forsberg G, Carducci MA, Pili R. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Dec 15;19(24):6891-901.
Key words:prostate cancer, tasquinimod, multicenter randomized study
http://www.ncbi.nlm.nih.gov/pubmed/24255071

2. Bailey E, Li L, Duffield AS, Ma HS, Huso DL, Small D. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21113-8.
Key words: FLT3, mutation, mice
http://www.ncbi.nlm.nih.gov/pubmed/24255108

3. Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH. Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer. 2013 Nov 15. doi:pii: S0959-8049(13)00932-5. 10.1016/j.ejca.2013.10.006. [Epub ahead of print]
Key words: lung cancer, erlotinib, phase II trial
http://www.ncbi.nlm.nih.gov/pubmed/24246704

4. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014 Jan;11(1):24-37.
Key words: immunotherapy, melanoma, lung cancer, kidney cancer
PubMed PMID: 24247168.
http://www.ncbi.nlm.nih.gov/pubmed/24247168

5. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene. 2013 Nov 25. doi: 10.1038/onc.2013.497. [Epub ahead of print]
Key words: prostate cancer, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24276248

6. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014 Jan 2;123(1):94-100.
Key words: cernolanib, FLT3, resistance
http://www.ncbi.nlm.nih.gov/pubmed/24227820

7. Joseph CG, Hwang H, Jiao Y, Wood LD, Kinde I, Wu J, Mandahl N, Luo J, Hruban RH, Diaz LA Jr, He TC, Vogelstein B, Kinzler KW, Mertens F, Papadopoulos N. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2014 Jan;53(1):15-24.
Key words: liposarcomas, osteosarcomas, synovial sarcomas
http://www.ncbi.nlm.nih.gov/pubmed/24190505

8. Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, Bivalacqua TJ. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. Urol Oncol. 2014 Jan;32(1):53.e9-53.e14.
Key words: cystectomy, bladder cancer, hospital-acquired complications
http://www.ncbi.nlm.nih.gov/pubmed/24239467

9. Le DT, Jaffee EM. Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res. 2013 Nov 15;19(22):6061-3.
Key words: immune response, tumor
http://www.ncbi.nlm.nih.gov/pubmed/24097857

10. Sharma D, Davidson NE. Obesity and breast cancer: a multipartite connection. J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):253-5.
Key words: obesity, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/24190309

11. Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolaños-Meade J. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2013 Nov 29. doi:pii: S1083-8791(13)00557-0. 10.1016/j.bbmt.2013.11.020. [Epub ahead of print]
Key words: lymphocyte infusions, HLA, bone marrow transplantation
http://www.ncbi.nlm.nih.gov/pubmed/24296490

1. Campian J, Sarai G, Ye X, Marur S, Grossman SA. The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2013 Oct 31. doi: 10.1002/hed.23535. [Epub ahead of print]
Key words: lymphopenia, head and neck cancer
http://www.ncbi.nlm.nih.gov/pubmed/24174270

2. Forde PM, Reiss KA, Zeidan AM, Brahmer JR. What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist. 2013 Oct 8. [Epub ahead of print]
Key words: lung cancer, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24105749

3. Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013 Oct 8. doi: 10.1038/pcan.2013.40. [Epub ahead of print]
Key words: prostate cancer, PSA, biochemical
http://www.ncbi.nlm.nih.gov/pubmed/24100642

4. Papadopoulos N, Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg MP, Bivalacqua T, Allaf ME, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Netto GJ. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013 Oct 11. [Epub ahead of print]
Key words: urothelial, urine, neoplasia, biomarkers
http://www.ncbi.nlm.nih.gov/pubmed/24121487

5. Suzman DL, Eisenberger MA. Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor. Eur Urol. 2013 Oct 16. doi:pii: S0302-2838(13)01075-0. 10.1016/j.eururo.2013.10.002. [Epub ahead of print]
Key words: metastatic, castration, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/24157242

6. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med. 2013 Oct 7. [Epub ahead of print]
Key words: breast cancer, epidermal
http://www.ncbi.nlm.nih.gov/pubmed/24099077

7. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013 Oct 25. [Epub ahead of print]
Key words: lung cancer, azacytine, immune
http://www.ncbi.nlm.nih.gov/pubmed/24162015

9. Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2013 Oct 10. doi: 10.1111/bjh.12599. [Epub ahead of print]
Key words: stroma, FLT3, extracellular
http://www.ncbi.nlm.nih.gov/pubmed/24116827

1. Chung CH, Bagheri A, D'Souza G. Epidemiology of oral human papillomavirus infection. Oral Oncol. 2013 Sep 27. doi:pii: S1368-8375(13)00685-4. 10.1016/j.oraloncology.2013.09.003. [Epub ahead of print]
Key words: epidemiology, papillomavirus
http://www.ncbi.nlm.nih.gov/pubmed/24080455

2. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-3687.
Key words: leukemia, duplication, myeloid
http://www.ncbi.nlm.nih.gov/pubmed/24002496

3. Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16121-16126.
Key words: hematopoietic, retinoic acid
http://www.ncbi.nlm.nih.gov/pubmed/24043786

4. Murray-Stewart T, Hanigan CL, Woster PM, Marton LJ, Casero RA Jr. Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. Mol Cancer Ther. 2013 Sep 26. [Epub ahead of print]
Key words: miRNA, deacetylase
http://www.ncbi.nlm.nih.gov/pubmed/23943804

5. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013 Sep 15;19(18):4917-24. doi: 10.1158/1078-0432.CCR-12-1972.
Key words: checkpoint, molecules, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23868869

6. Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Lacroix A, Li D, Mandelson MT, Olson SH, Petersen GM, Risch HA, Stolzenberg-Solomon RZ, Zheng W, Amundadottir L, Albanes D, Allen NE, Bamlet WR, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, Duell EJ, Elena J, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hassan M,Hutchinson A, Hunter DJ, Kooperberg C, Kurtz RC, Liu S, Overvad K, Palli D, Patel AV, Rabe KG, Shu XO, Slimani N, Tobias GS, Trichopoulos D, Van Den Eeden SK, Vineis P, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K,
Zeleniuch-Jacquotte A, Chanock SJ, Hoover RN, Hartge P, Kraft P. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One. 2013 Sep 13;8(9):e72311. doi: 10.1371/journal.pone.0072311.
Key words: pancreatic cancer, absolute, risk
http://www.ncbi.nlm.nih.gov/pubmed/24058443

7. Sharma D, Sukumar S. Big Punches Come in Nanosizes for Chemoprevention. Cancer Prev Res (Phila). 2013 Oct;6(10):1007-1010.
Key words: nanosizes, chemoprevention
http://www.ncbi.nlm.nih.gov/pubmed/24072677

8. Shaw PG, Chaerkady R, Wang T, Vasilatos S, Huang Y, Van Houten B, Pandey A, Davidson NE. Integrated proteomic and metabolic analysis of breast cancer progression. PLoS One. 2013 Sep 27;8(9):e76220.
Key words: breast cancer, proteomic
http://www.ncbi.nlm.nih.gov/pubmed/24086712

9. Wada S, Harris TJ, Tryggestad E, Yoshimura K, Zeng J, Yen HR, Getnet D, Grosso JF, Bruno TC, De Marzo AM, Netto GJ, Pardoll DM, Deweese TL, Wong J, Drake CG. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys. 2013 Sep 21. doi:pii: S0360-3016(13)02853-8. 10.1016/j.ijrobp.2013.07.015. [Epub ahead of print]
Key words: prostate cancer, autochtonous, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24064321

1. Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013.
Key words: mesenchymal, microenvironment, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23975882

2. Di Cello F, Flowers VL, Li H, Vecchio-Pagán B, Gordon B, Harbom K, Shin J, Beaty R, Wang W, Brayton C, Baylin SB, Zahnow CA. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer. 2013 Aug 6;12:90. doi: 10.1186/1476-4598-12-90.
Key words: smoke, mesenchymal, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23919753

3. Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, C H Wang W, Sheibani N, Carducci MA, Kachhap S, Hammers HJ. Screening assay for blood vessel maturation inhibitors. Biochem Biophys Res Commun. 2013 Aug 23;438(2):364-9. doi: 10.1016/j.bbrc.2013.07.077. Epub 2013 Jul 25.
Key words: inhibitor, blood vessel, maturation
http://www.ncbi.nlm.nih.gov/pubmed/23892038

4. Fuchs EJ. Selective allodepletion: have we finally found the holy grail? Biol Blood Marrow Transplant. 2013 Aug 13. doi:pii: S1083-8791(13)00353-4. 10.1016/j.bbmt.2013.08.004. [Epub ahead of print]
Key words: allodepletion, holy grail
http://www.ncbi.nlm.nih.gov/pubmed/23954761

5. Murray-Stewart T, Hanigan CL, Woster PM, Marton LJ, Casero RA. Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. Mol Cancer Ther. 2013 Aug 13. [Epub ahead of print]
Key words: miRNA, deacetylase, inhibition
http://www.ncbi.nlm.nih.gov/pubmed/23943804

6. Rangachari D, Brahmer JR. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol. 2013 Aug 11. [Epub ahead of print]
Key words: lung cancer, immune, targeting
http://www.ncbi.nlm.nih.gov/pubmed/23934510

7. Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials. Cancer. 2013 Aug 13. doi: 10.1002/cncr.28270. [Epub ahead of print]
Key words: docetaxel, prostate cancer, leuprolide
http://www.ncbi.nlm.nih.gov/pubmed/23943299

8. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013 Aug 20. doi: 10.1038/pcan.2013.28. [Epub ahead of print]
Key words: disulfiram, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23958896

9. Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print]
Key words: myelodysplastic, infection, bleeding
http://www.ncbi.nlm.nih.gov/pubmed/23841504

10. Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013 Aug 15;133(4):997-1005. doi: 10.1002/ijc.28083. Epub 2013 Mar 4.
Key words: temsirolimus, doxorubicin, sarcoma
http://www.ncbi.nlm.nih.gov/pubmed/23382028

11. Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, Vogelstein B, Zhou S. A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14717-22. doi: 10.1073/pnas.1313330110. Epub 2013 Aug 19.
Key words: nanoparticle, mice, tumors
http://www.ncbi.nlm.nih.gov/pubmed/23959886

12. Zeidan AM, Gore SD, McNally DL, Baer MR, Hendrick F, Mahmoud D, Davidoff AJ. Lenalidomide
performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013 Aug 6. doi: 10.1002/cncr.28298. [Epub ahead of print]
Key words: myelodysplastic, lenalidomide
http://www.ncbi.nlm.nih.gov/pubmed/23922173

1. Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Park BH, Lauring J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res. 2013 Jul 25. [Epub ahead of print]
Key words: isogenic, inhibitors, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23888070

2. Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, Wang W, Sheibani N, Carducci MA, Kachhap S, Hammers HJ. Screening assay for blood vessel maturation inhibitors. Biochem Biophys Res Commun. 2013 Jul 25. doi:pii: S0006-291X(13)01239-4. 10.1016/j.bbrc.2013.07.077. [Epub ahead of print]
Key words: screening, blood vessel, inhibitors
http://www.ncbi.nlm.nih.gov/pubmed/23892038

3. Gantt S, Casper C, Ambinder RF. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol. 2013 Jul 18. [Epub ahead of print]
Key words: nelfinavir, HIV, inhibitors
http://www.ncbi.nlm.nih.gov/pubmed/23872785

4. Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):678-85. doi: 10.1016/j.ijrobp.2013.03.032.
Key words: erlotinib, pancreatic cancer, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23773391

5. Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Verheul HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics. 2013 Jul 19;8(9). [Epub ahead of print]
Key words: deacetylase, prostate cancer, histone
http://www.ncbi.nlm.nih.gov/pubmed/23880963

6. Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS. CHFR silencing or microsatellite instability is associated with increased anti-tumor activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer. 2013 Jul 20. doi: 10.1002/ijc.28390. [Epub ahead of print]
Key words: colorectal cancer, docetaxel, instability
http://www.ncbi.nlm.nih.gov/pubmed/23873170

7. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of seneca valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013 Jul 17;105(14):1059-65. doi: 10.1093/jnci/djt130. Epub 2013 Jun 5.
Key words: tropism, Seneca valley, lung cancer
PubMed PMID: 23739064.
http://www.ncbi.nlm.nih.gov/pubmed/23739064

8. Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG. Effect of Chelators on the Pharmacokinetics of (99m)Tc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). J Med Chem. 2013 Jul 22. [Epub ahead of print]
Key words: antigen, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23799782

9. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, Espinoza-Delgado I, Sukumar S, Gabrielson E, Davidson NE. Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clin Cancer Res. 2013 Jul 15;19(14):4008-16. doi: 10.1158/1078-0432.CCR-13-0033. Epub 2013 May 29.
Key words: vorinostat, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23719261

10. Vendetti FP, Rudin CM. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther. 2013 Jul 17. [Epub ahead of print]
Key words: DNA, epigenetic, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/23859704

1. Haffner MC, Pellakuru LG, Ghosh S, Lotan TL, Nelson WG, De Marzo AM, Yegnasubramanian S. Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease. Cell Cycle. 2013 Jun 15;12(12):1835-41. doi: 10.4161/cc.25010. Epub 2013 May 15.
Key words: polycomb, correlation
http://www.ncbi.nlm.nih.gov/pubmed/23676216

2. Howard JD, Moriarty WF, Park J, Riedy K, Panova IP, Chung CH, Suh KY, Levchenko A, Alani RM. Notch signaling mediates melanoma-endothelial cell communication and melanoma cell migration. Pigment Cell Melanoma Res. 2013 Jun 16. doi: 10.1111/pcmr.12131. [Epub ahead of print]
Key words: melanoma, endothelial
http://www.ncbi.nlm.nih.gov/pubmed/23773728

3. Jeschke J, O'Hagan HM, Zhang W, Vatapalli R, Calmon MF, Danilova L, Nelkenbrecher C, Van Neste L, Bijsmans IT, Van Engeland M, Gabrielson E, Schuebel KE, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. Clin Cancer Res. 2013 Jun 15;19(12):3201-11. doi: 10.1158/1078-0432.CCR-12-3751. Epub 2013 Apr 29.
Key words: dioxygenase, breast cancer, anthracyclines
http://www.ncbi.nlm.nih.gov/pubmed/23630167

4. Kanakry JA, Ambinder RF. EBV-related lymphomas: new approaches to treatment. Curr Treat Options Oncol. 2013 Jun;14(2):224-36. doi: 10.1007/s11864-013 0231-y. PubMed PMID: 23549980; PubMed Central
Key words: EBV, lymphoma
http://www.ncbi.nlm.nih.gov/pubmed/23549980

5. Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR. Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. J Med Chem. 2013 Jun 13;56(11):4224-35. doi: 10.1021/jm301718c. Epub 2013 Jun 4.
Key words: prostate cancer, peptidomimetic
http://www.ncbi.nlm.nih.gov/pubmed/23692593

6. Michiel Sedelaar JP, Dalrymple SS, Isaacs JT. Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate. 2013 Jun 15. doi: 10.1002/pros.22677. [Epub ahead of print]
Key words: abiraterone, hypogonadal, xenograft, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23775398

7. Nadal R, McMahan ZH, Antonarakis ES. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer. Clin Genitourin Cancer. 2013 Jun 29. doi:pii: S1558-7673(13)00139-0. 10.1016/j.clgc.2013.05.008. [Epub ahead of print]
Key words: prostate cancer, genitourin, fasciitis
http://www.ncbi.nlm.nih.gov/pubmed/23820064

8. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013 Jun 5. [Epub ahead of print]
Key words: tropism, senca valley
http://www.ncbi.nlm.nih.gov/pubmed/23739064

9. Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of surface CXCR4 expression as a mechanism of chemotherapy resistance in pediatric acute myeloid leukemia. Mol Cancer Res. 2013 Jun 10. [Epub ahead of print]
Key words: CXCR4, leukemia, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23754844

10. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, Espinoza-Delgado I, Sukumar S, Gabrielson E, Davidson NE. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clin Cancer Res. 2013 Jun 27. [Epub ahead of print]
Key words: breast cancer, vorinostat
http://www.ncbi.nlm.nih.gov/pubmed/23719261

11. Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013 Jun 1;73(11):3248-61. doi: 10.1158/0008-5472.CAN-12-1578. Epub 2013 Apr 11.
Key words: PIK3CA, epithelial, immortalize
PubMed PMID: 23580570; PubMed Central PMCID: PMC3674106.
http://www.ncbi.nlm.nih.gov/pubmed/23580570

1. Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L; Blood and Marrow Transplant Clinical Trials Network. Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. Biol Blood Marrow Transplant. 2013 Mar;19(3):481-5. doi: 10.1016/j.bbmt.2012.12.003. Epub 2012 Dec 12.
Key words: transplant, blood, marrow, lymphocyte
http://www.ncbi.nlm.nih.gov/pubmed/23247045

2. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer. Cancer Invest. 2013 Mar;31(3):183-8. doi: 10.3109/07357907.2013.767342.
Key words: lung cancer, lymphopenia, stage III
http://www.ncbi.nlm.nih.gov/pubmed/23432821

3. Connolly R, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol. 2013 Mar 29. doi:pii: S0014-2999(13)00251-3. 10.1016/j.ejphar.2013.02.057. [Epub ahead of print]
Key words: breast cancer, neoadjuvant, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23545358

4. Cope L, Wu RC, Shih IeM, Wang TL. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecol Oncol. 2013 Mar;128(3):500-5. doi: 10.1016/j.ygyno.2012.11.031. Epub 2012 Nov 28.
Key words: ovarian cancer, genome, aberration, chromosomal
http://www.ncbi.nlm.nih.gov/pubmed/23200914

5. Durand CM, Ambinder RF. Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication. Curr Opin Oncol. 2013 Mar;25(2):180-6. doi: 10.1097/CCO.0b013e32835d814a.
Key words: HIV, hematopoietic, eradication
http://www.ncbi.nlm.nih.gov/pubmed/23385862

6. Holdhoff M, Rosner GL, Alcorn S, Grossman SA. 'Elderly' patients with newly diagnosed glioblastoma deserve optimal care. J Neurooncol. 2013 Mar 23. [Epub ahead of print]
Key words: glioblastoma, elderly
http://www.ncbi.nlm.nih.gov/pubmed/23526408

7. Hossain MZ, Gilbert SF, Patel K, Ghosh S, Bhunia AK, Kern SE. Biological clues to potent DNA-damaging activities in food and flavoring. Food Chem Toxicol. 2013 May;55:557-67. doi: 10.1016/j.fct.2013.01.058. Epub 2013 Feb 8.
Key words: DNA damage, food, flavoring
http://www.ncbi.nlm.nih.gov/pubmed/23402862

8. Manning ML, Williams SA, Jelinek CA, Kostova MB, Denmeade SR. Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. J Immunol. 2013 Mar 15;190(6):2567-74. doi: 10.4049/jimmunol.1200856. Epub 2013 Feb 11.
Key words: prostate cancer, seminal plasma, iC3b
http://www.ncbi.nlm.nih.gov/pubmed/23401592

9. Murray-Stewart T, Woster PM, Casero RA Jr. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids. 2013 Mar 19. [Epub ahead of print]
Key words: leukemia, cadherin, demethylase, myeloid
http://www.ncbi.nlm.nih.gov/pubmed/23508577

10. Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2013 Mar 29. [Epub ahead of print]
Key words: pemetrexed, lung cancer, metastatic
http://www.ncbi.nlm.nih.gov/pubmed/23546045

11. Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol. 2013 Mar 21. [Epub ahead of print]
Key words: lung cancer, dabrafenib
http://www.ncbi.nlm.nih.gov/pubmed/23524406

12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122. Review.
Key words: cancer, genome, landscapes
http://www.ncbi.nlm.nih.gov/pubmed/23539594

13. Zinn RL, Gardner EE, Dobromilskaya I, Murphy S, Marchionni L, Hann CL, Rudin CM. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol Cancer. 2013 Mar 2;12:16. doi: 10.1186/1476-4598-12-16.
Key words: lung cancer, chloroquine
http://www.ncbi.nlm.nih.gov/pubmed/23452820

14. Zinn RL, Gardner EE, Marchionni L, Murphy SC, Dobromilskaya I, Hann CL, Rudin CM. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther. 2013 Mar 20. [Epub ahead of print]
Key words: lung cancer, IGF-1R, ERK
http://www.ncbi.nlm.nih.gov/pubmed/23515613

15. Yegnasubramanian S, Maitra A. Aiming for the outliers: cancer precision medicine through targeting kinases with extreme expression. Cancer Discov. 2013 Mar;3(3):252-4. doi: 10.1158/2159-8290.CD-13-0016.
Key words: kinases, expression, outliers
http://www.ncbi.nlm.nih.gov/pubmed/23475875

1. Chang CL, Hsu YT, Wu CC, Lai YZ, Wang C, Yang YC, Wu TC, Hung CF. Dose-dense
chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 2013 Jan 1;73(1):119-27. doi: 10.1158/0008-5472.CAN-12-2225. Epub 2012 Oct 29.
Key words: antitumor, chemotherapy, dose-dense, immune
http://www.ncbi.nlm.nih.gov/pubmed/23108141

2. Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng CX, Ye Z,
Jang YY. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology. 2013 Jan 16. doi:
10.1002/hep.26237. [Epub ahead of print]
Key words: screening, liver, disease, stem cells
http://www.ncbi.nlm.nih.gov/pubmed/23325555

3. Connolly R, Nguyen NK, Sukumar S. Molecular Pathways: Current Role and Future
Directions of the Retinoic Acid Pathway In Cancer Prevention and Treatment. Clin Cancer Res. 2013 Jan 15. [Epub ahead of print]
Key words: retinoic, acid, prevention
http://www.ncbi.nlm.nih.gov/pubmed/23322901

4. Heikamp EB, Powell JD. Sensing the immune microenvironment to coordinate T
cell metabolism, differentiation & function. Semin Immunol. 2013 Jan 14. doi:pii: S1044-5323(12)00108-X. 10.1016/j.smim.2012.12.003. [Epub ahead of print]
Key words: T cell, differentiation, metabolism
http://www.ncbi.nlm.nih.gov/pubmed/23332779

5. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, Symons H,
Bolaños-Meade J, Gladstone DE, Swinnen LJ, Luznik L, Fuchs EJ, Jones RJ, Ambinder RF. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T-cell lymphoma. Biol Blood Marrow Transplant. 2013 Jan 28. doi:pii: S1083-8791(13)00021-9.
10.1016/j.bbmt.2013.01.006. [Epub ahead of print]
Key words: lymphoma, allogeneic, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/23370119

6. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F,
Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR,
Davidson NE. Breast Cancer Follow-Up and Management After Primary Treatment:
American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013 Jan 14. [Epub ahead of print]
Key words: breast cancer, follow-up, primary treatment
http://www.ncbi.nlm.nih.gov/pubmed/23129741

7. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res. 2013 Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov 20. PubMed PMID: 23169436;
Key words: regression, reinduction, durable
http://www.ncbi.nlm.nih.gov/pubmed/23169436

8. Luitweiler EM, Henson BW, Pryce EN, Patel V, Coombs G, McCaffery JM, Desai PJ. Interactions of the KSHV nuclear egress complex: ORF69 is a potent factor for re-modeling cellular membranes. J Virol. 2013 Jan 30. [Epub ahead of print]
Key words: cellular membranes, ORF69
http://www.ncbi.nlm.nih.gov/pubmed/23365436

9. Matthaei H, Molin MD, Maitra A. Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Biol. 2013;980:1-12. doi: 10.1007/978-1-62703-287-2_1.
Key words: identification, precursors, pancreatic cancer
http://www.ncbi.nlm.nih.gov/pubmed/23359146

10. Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P. MLL-rearranged acute
lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol. 2013 Jan 7. doi: 10.1111/bjh.12205. [Epub ahead of print]
Key words: leukemia, stem cell, bone marrow, stroma
http://www.ncbi.nlm.nih.gov/pubmed/23294096

11. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D. Mutations of
FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2013 Jan;27(1):48-55. doi: 10.1038/leu.2012.191. Epub 2012 Jul 13.
Key words: mutations, resistance, tyrosine
http://www.ncbi.nlm.nih.gov/pubmed/22858906

1. Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Egeler RM, Arceci RJ. Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity. Br J Haematol. 2012 Nov;159(3):299-310.
Key words: phage, monoclonal, cytolytic
http://www.ncbi.nlm.nih.gov/pubmed/22934889

2. Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22;120(22):4285-91.
Key words: sickle cell, cyclophosphamide, donor
http://www.ncbi.nlm.nih.gov/pubmed/22955919

3. Isaacs JT, Antony L, Dalrymple S, Brennen WN, Gerber S, Hammers H, Wissing MD, Kachhap SK, Luo J, Xing L, Bjork P, Olsson A, Björk A, Leanderson T. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2012 Nov 13. [Epub ahead of print]
Key words: HDAC4, allosteric, signaling
http://www.ncbi.nlm.nih.gov/pubmed/23149916

4. Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL, Drake CG. Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. Prostate. 2012 Nov 5. doi: 10.1002/pros.22606. [Epub ahead of print]
Key words: prostatisis, aotoimmune
http://www.ncbi.nlm.nih.gov/pubmed/23129407

5. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov;97(11):1736-42.
Key words: leukemia, mitoxantrone, flavopiridol
http://www.ncbi.nlm.nih.gov/pubmed/22733022

6. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Nov 19. [Epub ahead of print]
Key words: arabinoside, leukemia, selective checkpoint
http://www.ncbi.nlm.nih.gov/pubmed/23092873

7. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012 Nov 28;4(162):162ra154.
Key words: circulation, chromosomal, sequencing
http://www.ncbi.nlm.nih.gov/pubmed/23197571

8. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable Cancer Regression Off-treatment and Effective Re-induction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res. 2012 Nov 20. [Epub ahead of print]
Key words: cancer regression, anti-PD, Re-induction
http://www.ncbi.nlm.nih.gov/pubmed/23169436

9. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):E3367-76.
Key words: breast cancer, hypoxia, coactivator
http://www.ncbi.nlm.nih.gov/pubmed/23129632

10. Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92.
Key words: papillomavirus, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/23163511

11. Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek MA. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr. 2012 Nov;26(11):1315-24.
Key words: sunitinib, human plasma, pharmacokinetic
http://www.ncbi.nlm.nih.gov/pubmed/22259028

12. Ren YR, Chaerkady R, Hu S, Wan J, Qian J, Zhu H, Pandey A, Kern SE. Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10.
Key words: mesothelin, therapeutic, control locus
http://www.ncbi.nlm.nih.gov/pubmed/23025254

13. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012 Nov 15;120(20):4205-14.
Key words: Myeloid, terminal, FLT3
http://www.ncbi.nlm.nih.gov/pubmed/23012328

14. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J. 2012 Nov;18(6):642-52.
Key words: vaccines, pancreatic cancer
http://www.ncbi.nlm.nih.gov/pubmed/23187853

1. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, Isaacs WB, Platz EA. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1774-82. doi: 10.1158/1055-9965.EPI-12-0458. Epub 2012 Aug 2.
Key words: IL10, prostate cancer, recurrence
http://www.ncbi.nlm.nih.gov/pubmed/22859398

2. Huo JS, Zambidis ET. Pivots of pluripotency: The roles of non-coding RNA in regulating embryonic and induced pluripotent stem cells. Biochim Biophys Acta. 2012 Oct 24. doi:pii: S0304-4165(12)00300-5. 10.1016/j.bbagen.2012.10.014. [Epub ahead of print]
Key words: RNA, stem cells, pluripotent
http://www.ncbi.nlm.nih.gov/pubmed/23104383

3. Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub 2012 Mar 6.
Key words: prostate cancer, BAT, paradigm shifting
http://www.ncbi.nlm.nih.gov/pubmed/22396319

4. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten K, Peterson KL, Schneider P, Mackey K, Freshwater T, Levis M, McDevitt M, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Issacs R, Kaufmann SH. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Nov 12. [Epub ahead of print]
Key words: arabinoside, leukemia, cytosine
http://www.ncbi.nlm.nih.gov/pubmed/23092873

5. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012 Oct 18. doi:pii: S0022-5347(12)04485-0. 10.1016/j.juro.2012.08.028. [Epub ahead of print]
Key words: retropubic, prostatectomy
http://www.ncbi.nlm.nih.gov/pubmed/23083655

6. Raabe EH, Eberhart CG. Methylome alterations "mark" new therapeutic opportunities in glioblastoma. Cancer Cell. 2012 Oct 16;22(4):417-8. doi: 10.1016/j.ccr.2012.10.001.
Key words: methylome, glioblastoma
http://www.ncbi.nlm.nih.gov/pubmed/23079650

7. Ren YR, Chaerkady R, Hu S, Wan J, Qian J, Zhu H, Pandey A, Kern SE. Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10. doi: 10.1021/pr300797v. Epub 2012 Oct 12.
Key words: mesothelin, control lucus
http://www.ncbi.nlm.nih.gov/pubmed/23025254

8. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.
Key words: lung cancer, SOX2, genomic analysis
http://www.ncbi.nlm.nih.gov/pubmed/22941189

9. Terezakis SA, Kasamon YL. Tailored strategies for radiation therapy in classical Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2012 Oct;84(1):71-84. doi: 10.1016/j.critrevonc.2012.02.006.
Key words: Hodgkin's lymphoma, radiation therapy
http://www.ncbi.nlm.nih.gov/pubmed/22463873

1. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet. 2012 Oct;13(10):693-704. doi: 10.1038/nrg3246. Epub 2012 Sep 11.
Key words: telomere, syndromes
http://www.ncbi.nlm.nih.gov/pubmed/22965356

2. Boikos SA, Hammers HJ. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol. 2012 Sep 4. [Epub ahead of print]
Key words: denosumab, bisphosphonate, hypercalcemia
PubMed PMID: 22949145.
http://www.ncbi.nlm.nih.gov/pubmed/22949145

3. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. Epub 2012 Aug 21.
Key words: tumor stroma, fibroblast, prodrug
http://www.ncbi.nlm.nih.gov/pubmed/22911669

4. Chen S, Principessa L, Isaacs JT. Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate. 2012 Sep 15;72(13):1478-89. doi: 10.1002/pros.22503. Epub 2012 Mar 6.
Key words: prostaspheres, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22396312

5. Chu SH, Heiser D, Li L, Kaplan I, Collector M, Huso D, Sharkis SJ, Civin C, Small D. FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm. Cell Stem Cell. 2012 Sep 7;11(3):346-58.
Key words: neoplasm, quiescence, homeostasis, myeloproliferative
http://www.ncbi.nlm.nih.gov/pubmed/22958930

6. D'Souza G, Burk RD, Zhong Y, Minkoff H, Massad LS, Xue X, Watts DH, Anastos K, Palefsky JM, Levine AM, Colie C, Castle PE, Strickler HD. Cervicovaginal human papillomavirus (HPV)-infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and nononcogenic HPV types in a cohort of HIV-positive and HIV-negative women. Int J Cancer. 2012 Sep 15;131(6):1472-8. doi: 10.1002/ijc.27363. Epub 2012 Jan 3.
Key words: HPV, hysterectomy, tissue tropism
http://www.ncbi.nlm.nih.gov/pubmed/22120980

7. Fuchs EJ. Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol. 2012 Sep 5. [Epub ahead of print]
Key words: T cell, bone marrow, leukocyte, grafts
http://www.ncbi.nlm.nih.gov/pubmed/22954723

8. Jones RJ. Haploidentical transplantation - repurposing cyclophosphamide. Biol Blood Marrow Transplant. 2012 Sep 27. pii: S1083-8791(12)00370-9. doi: 10.1016/j.bbmt.2012.09.005. [Epub ahead of print]
Key words: cyclophosphamide, haploidentical, transplantation
PubMed PMID: 23022466.
http://www.ncbi.nlm.nih.gov/pubmed/22965356

9. McMillan R, Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res. 2012 Sep 15;18(18):4883-8. Epub 2012 Jun 19.
Key words: hedgehog, signaling , pathway
http://www.ncbi.nlm.nih.gov/pubmed/22718857

10. Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM. Characterization of a full-length infectious cDNA clone and a green fluorescent protein reporter derivative of the oncolytic picornavirus SVV-001. J Gen Virol. 2012 Sep 12. [Epub ahead of print]
Key words: cDNA, picornavirus, green
http://www.ncbi.nlm.nih.gov/pubmed/22971818

11. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.
Key words: lung cancer, genomic analysis, SOX2
http://www.ncbi.nlm.nih.gov/pubmed/22941189

12. Santa-Maria CA, Cimino-Mathews A, Moseley KF, Wolff AC, Blakeley JO, Connolly RM. Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer-Associated Leptomeningeal Disease. Clin Breast Cancer. 2012 Sep 22. pii: S1526-8209(12)00174-7. doi: 10.1016/j.clbc.2012.07.010. [Epub ahead of print]
Key words: breast cancer, methotrexate, leptomeningeal
http://www.ncbi.nlm.nih.gov/pubmed/23010203

13. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012 Sep 25. [Epub ahead of print]
Key words: terminal, FLT3, differentiation
http://www.ncbi.nlm.nih.gov/pubmed/23012328

14. Suarez L, Gore SD. Cp-jeez! Aza-natomy! Blood. 2012 Sep 20;120(12):2354-5.
Key words: cp-jeez, aza-natomy
http://www.ncbi.nlm.nih.gov/pubmed/22996655

15. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev. 2012 Sep;249(1):43-58. doi: 10.1111/j.1600-065X.2012.01152.x.
Key words: mTOR, metabolism, T-cell
PubMed PMID: 22889214; PubMed Central PMCID: PMC3419491.
http://www.ncbi.nlm.nih.gov/pubmed/22889214

1. Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatr Blood Cancer. 2012 Aug 8. doi: 10.1002/pbc.24264. [Epub ahead of print]
Key words: clofarabine, cyclophosphamide, leukemia
http://www.ncbi.nlm.nih.gov/pubmed/22887831

2. Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Maarten Egeler R, Arceci RJ. Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity. Br J Haematol. 2012 Aug 30. doi: 10.1111/bjh.12033. [Epub ahead of print]
Key words: anti-CD1A, monoclonal antibody
http://www.ncbi.nlm.nih.gov/pubmed/22934889

3. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. Epub 2012 Aug 21.
Key words: fibroblasts, tumor stroma, protein-activated prodrug
http://www.ncbi.nlm.nih.gov/pubmed/22911669

4. Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano. 2012 Sep 25;6(9):7752-62.
Key words: nanoplex, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22866897

5. Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 2012 Aug 4. [Epub ahead of print]
Key words: breast cancer therapy, PI3K/Akt/mTOR
http://www.ncbi.nlm.nih.gov/pubmed/22865098

6. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, Issacs WB, Platz EA. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2012 Sept 25. [Epub ahead of print]
Key words: IL-10, immune response, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22859398

7. Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, Diaz LA Jr. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol. 2012 Aug 29. [Epub ahead of print]
Key words: glibolastoma, molecular biomarkers
http://www.ncbi.nlm.nih.gov/pubmed/22930388

8. Kreitler D, Capuano CM, Henson BW, Pryce EN, Anacker D, McCaffery JM, Desai PJ. The assembly domain of the small capsid protein of Kaposi's sarcoma-associated herpesvirus. J Virol. 2012 Aug 22. [Epub ahead of print]
Key words: small capsid protein, Kaposi's sarcoma, herpesvirus
http://www.ncbi.nlm.nih.gov/pubmed/22915821

9. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res. 2012 Aug 15;18(16):4277-84.
Key words: pancreatic cancer, stem cells
http://www.ncbi.nlm.nih.gov/pubmed/22896694

10. Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood. 2012 Aug 27. [Epub ahead of print]
Key words: fluvastatin, FLT3 glycosylation, murine cells, leukemia
http://www.ncbi.nlm.nih.gov/pubmed/22927251

11. Zeidan A, Bolanños-Meade J, Kasamon Y, Aoki J, Borowitz M, Swinnen L, Symons H, Luznik L, Fuchs E, Jones R, Ambinder R. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2012 Aug 27. [Epub ahead of print]
Key words: histiocytic sarcoma, stem cell transplant
http://www.ncbi.nlm.nih.gov/pubmed/22845310

1. Bhan S, Chuang A, Negi SS, Glazer CA, Califano JA. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. Oncol Rep. 2012 Jul 25. doi: 10.3892/or.2012.1934. [Epub ahead of print]
Key words: keratinocytes, oral, apoptosis
PubMed PMID: 22842486.
http://www.ncbi.nlm.nih.gov/pubmed/22842486

2. Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, de Wilde RF, Zhang Z, Huso D, Zhao M, Rudek M, Stearns V, Maitra A, Sukumar S. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis. 2012 Jul 25. [Epub ahead of print]
Key words: breast cancer, curcumin, polymeric, nanoparticle
http://www.ncbi.nlm.nih.gov/pubmed/22831956

3. Denmeade SR, Isaacs JT. Engineering enzymatically activated "Molecular Grenades" for cancer. Oncotarget. 2012 Jul 22. [Epub ahead of print]
Key words: grenade, molecular, engineering
http://www.ncbi.nlm.nih.gov/pubmed/22837432

4. Manning ML, Kostova M, Williams SA, Denmeade SR. Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid. Prostate. 2012 Aug 1;72(11):1233-8. doi: 10.1002/pros.22474. Epub 2011 Dec 28.
Key words: seminal, purified, proteolytic, contamination
http://www.ncbi.nlm.nih.gov/pubmed/22213008

5. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012 Aug;4(4):167-78.
Key words: prostate cancer, hormonal, therapy, androgen
http://www.ncbi.nlm.nih.gov/pubmed/22852027

6. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM. Global levels of H3K27me3 Track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol. 2012 Aug;181(2):560-9.
Key words: prostate cancer, deregulated, MYC, H3K27me3
http://www.ncbi.nlm.nih.gov/pubmed/22713676

7. Wenzel J, Jones RA, Klimmek R, Krumm S, Darrell LP, Song D, Stearns V, Ford JG. Cancer support and resource needs among african american older adults. Clin J Oncol Nurs. 2012 Aug 1;16(4):372-7.
Key words: support, resource, cancer, African, American
http://www.ncbi.nlm.nih.gov/pubmed/22842688

8. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2012 Jul 13. doi: 10.1038/leu.2012.191. [Epub ahead of print]
Key words: tyrosine, inhibitors, kinase, FLT3
http://www.ncbi.nlm.nih.gov/pubmed/22858906

1. Chun YS, Yoshida T, Mori T, Huso DL, Zhang Z, Stearns V, Perkins B, Jones RJ, Sukumar S. Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors. Breast Cancer Res Treat. 2012 Jul 1. [Epub ahead of print]
Key words: breast cancer, mammary, liposomal
http://www.ncbi.nlm.nih.gov/pubmed/22752247

2. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012 Jun 27;4(140):140ra86.
Key words: endothelial, prostate cancer, prodrug
http://www.ncbi.nlm.nih.gov/pubmed/22745436

3. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40.
Key words: evolution, blockade, EGFR, colorectal cancer
http://www.ncbi.nlm.nih.gov/pubmed/22722843

4. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012 Jul 3. [Epub ahead of print]
Key words: T cell,cyclophosphamide, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/22761338

5. McMillan R, Matsui W. Molecular Pathways: The hedgehog signaling pathway in cancer. Clin Cancer Res. 2012 Jun 19. [Epub ahead of print]
Key words: hedgehog, pathways, molecular, signaling
http://www.ncbi.nlm.nih.gov/pubmed/22718857

6. Nwankwo N, Zhang Z, Wang T, Collins C, Resta L, Ermisch S, Day J, Decker R, Kornberg L, Nicol S, Thornton D, Armstrong DK, Carducci MA. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs. 2012 Jul 6. [Epub ahead of print]
Key words: enzastaurin, bevacuzimab
http://www.ncbi.nlm.nih.gov/pubmed/22766773

7. Pan F, Barbi J, Pardoll DM. Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target. Oncoimmunology. 2012 Jul 1;1(4):510-515.
Key words: T cell, differentiation, metabolism
http://www.ncbi.nlm.nih.gov/pubmed/22754770

8. Rudin CM. Vismodegib. Clin Cancer Res. 2012 Jun 15;18(12):3218-22. Epub 2012 Jun 7.
Key words: vismodegib
http://www.ncbi.nlm.nih.gov/pubmed/22679179

9. Smith BD. Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. Am J Med. 2012 Jul;125(7 Suppl):S26-30.
Key words: myelodysplastic, syndrome
http://www.ncbi.nlm.nih.gov/pubmed/22735750

10. Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18.
Key words: cyclophosphamide, leukemia, relapse, clofarabine
http://www.ncbi.nlm.nih.gov/pubmed/22594769

1. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012 Jun 6. doi: 10.1002/cncr.27689. [Epub ahead of print]
Key words: prostate cancer, prostatectomy, Ki67
http://www.ncbi.nlm.nih.gov/pubmed/22674438

2. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2012 May 22. [Epub ahead of print]
Key words: cetuximab, colorectal cancer, sorafenib
http://www.ncbi.nlm.nih.gov/pubmed?term=22615057

3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 2. [Epub ahead of print]
Key words: adavanced cancer, antibody, anti-PD-L1
http://www.ncbi.nlm.nih.gov/pubmed/22658128

4. Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201.
Key words: lung cancer, crizotinib
http://www.ncbi.nlm.nih.gov/pubmed/22594847

5. Greenblatt S, Small D. FLT3 in lineage specification and plasticity. Oncotarget. 2012 May 27. [Epub ahead of print]
Key words: FLT3, plasticity
http://www.ncbi.nlm.nih.gov/pubmed/22643831

6. Jelovac D, Armstrong DK. Role of Farletuzumab in Epithelial Ovarian Carcinoma. Curr Pharm Des. 2012 May 14. [Epub ahead of print]
Key words: farletuzumab, ovarian carcinoma, epithelial
http://www.ncbi.nlm.nih.gov/pubmed?term=22591419

7. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012 Jun 4. [Epub ahead of print]
Key words: breast cancer, PIK3CA, peripheral blood
http://www.ncbi.nlm.nih.gov/pubmed/22421194

8. Jelovac D, Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol. 2012 Jun;13(2):230-9.
Key words: breast cancer, treatment, HER2
http://www.ncbi.nlm.nih.gov/pubmed/22410709

9. Keenan BP, Jaffee EM. Whole cell vaccines-past progress and future strategies. Semin Oncol. 2012 Jun;39(3):276-86.
Key words: past, vaccines, future
http://www.ncbi.nlm.nih.gov/pubmed/22595050

10. Khaliq W, Meyer CF, Uzoaru I, Wolf RM, Antonarakis ES. Prostate angiosarcoma: is there any association with previous radiation therapy? BJU Int. 2012 May 15. doi: 10.1111/j.1464-410X.2012.11202.x. [Epub ahead of print]
Key words: radiation therapy, angiosarcoma
http://www.ncbi.nlm.nih.gov/pubmed?term=22583810

11. Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical Development of Listeria monocytogenes-Based Immunotherapies. Semin Oncol. 2012 Jun;39(3):311-22.
Key words: listeria, monocytogenes
http://www.ncbi.nlm.nih.gov/pubmed/22595054

12. Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012 May 24. [Epub ahead of print]
Key words: PET, noise, uptake value
http://www.ncbi.nlm.nih.gov/pubmed/22627001

13. Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A(2A) adenosine receptor. Cancer Immunol Immunother. 2012 Jun;61(6):917-26. Epub 2011 Nov 25.
Key words: adenosine, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/22116345

14. Waickman AT, Powell JD. Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol. 2012 May 15;188(10):4721-9.
Key words: rapamycin, antigen recognition, T cells
PubMed Central PMCID: PMC3347776.
http://www.ncbi.nlm.nih.gov/pubmed?term=22556133

15. Vogelstein B, Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Velculescu VE. Response to comments on "the predictive capacity of personal genome sequencing". Sci Transl Med. 2012 May 23;4(135):135lr3.
Key words: genome, sequencing, predictive

1. Antonarakis ES, Drake CG. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol. 2012 May;24(3):258-65.
Key words: immunotherapy, androgen, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22410456

2. Armanios M. An emerging role for the conserved telomere component 1 (CTC1) in human genetic disease. Pediatr Blood Cancer. 2012 May 3. doi: 10.1002/pbc.24200. [Epub ahead of print]
Key words: telomere, genetic disease, CTC1
http://www.ncbi.nlm.nih.gov/pubmed/22556055

3. Baylin SB. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc Am Thorac Soc. 2012 May;9(2):64-5.
Key words: epigenome, tumorigenesis, translational
http://www.ncbi.nlm.nih.gov/pubmed/22550245

4. Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate. 2012 May 1;72(6):638-48. doi: 10.1002/pros.21467. Epub 2011 Aug 11.
Key words: tasquinimod, prostate cancer, rebound, fractionated
http://www.ncbi.nlm.nih.gov/pubmed/21837778

5. Drake CG, Antonarakis ES. Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol. 2012 May;22(3):197-202.
Key words: immunological, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22328018

6. Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D, Collisson E, Zhu J, Yegnasubramanian S, Matsui W, Baylin SB. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 2012 May;22(5):837-49. Epub 2012 Mar 5.
Key words: DNA, hypermethylation, signature
http://www.ncbi.nlm.nih.gov/pubmed/22391556

7. Easwaran H, Baylin SB. Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes! Clin Cancer Res. 2012 Apr 15;18(8):2121-3. Epub 2012 Feb 27.
Key words: biomarkers, EGFR, response
http://www.ncbi.nlm.nih.gov/pubmed/22371454

8. Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012 Apr 10;10:70.
Key words: immunotherapy, microenvironment, integrative
http://www.ncbi.nlm.nih.gov/pubmed/22490302

9. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-32. Epub 2012 Feb 16.
Key words: Hodgkin, lymphoma, ABVD
http://www.ncbi.nlm.nih.gov/pubmed/22343727

10. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs. 2012 May 1. [Epub ahead of print]
Key words: FTS, pancreatic cancer
http://www.ncbi.nlm.nih.gov/pubmed/22547163

11. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012 Apr 25. [Epub ahead of print]
Key words: genome, sequencing, predictive
http://www.ncbi.nlm.nih.gov/pubmed/22472521

12. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Phase 2 study of single agent navitoclax (ABT 263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Apr 11. [Epub ahead of print]
Key words: navitoclax, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/22496272

13. Sanguineti G, Sormani MP, Marur S, Gunn GB, Rao N, Cianchetti M, Ricchetti F, McNutt T, Wu B, Forastiere A. Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):235-42. Epub 2011 Nov 19.
Key words: radiation therapy, GI cancer, mucositis
http://www.ncbi.nlm.nih.gov/pubmed/22104358

1. Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets. 2012 Apr;16(4):365-76. Epub 2012 Mar 13.
Key words: angiogenesis, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22413953

2. Emens LA. Re-purposing cancer therapeutics for breast cancer immunotherapy. Cancer Immunol Immunother. 2012 Mar 28. [Epub ahead of print]
Key words: immunotherapy, re-purposing, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/22454154

3. Gladstone DE, Blackford A, Cho E, Swinnen L, Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade J, Jones RJ. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):132-7. Epub 2012 Jan 28.
Key words: IGHV, leukemia, chronic
http://www.ncbi.nlm.nih.gov/pubmed/22285608

4. Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S; for the Adult Brain Tumor Consortium, Baltimore, MD. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol. 2012 Apr;14(4):511-517. Epub 2012 Feb 8.
Key words: glioma, terameprocol
http://www.ncbi.nlm.nih.gov/pubmed/22323663

5. Greenblatt S, Li L, Slape C, Nguyen B, Novak R, Duffield A, Huso D, Desiderio S, Borowitz MJ, Aplan P, Small D. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood. 2012 Mar 22;119(12):2883-94. Epub 2012 Feb 8.
Key words: leukemia, mouse, mutation
http://www.ncbi.nlm.nih.gov/pubmed/22323452

6. Guo H, Ma O, Speck NA, Friedman AD. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis. Blood. 2012 Mar 26. [Epub ahead of print]
Key words: monopoiesis, granulopoiesis, Runx1, Cebpa
http://www.ncbi.nlm.nih.gov/pubmed/22451420

7. Paller CJ, Antonarakis E. Sipuleucel-T for the treatment of metastatic prostate cancer: Promise and challenges. Hum Vaccin Immunother. 2012 Apr 1;8(4). [Epub ahead of print]
Key words: sipuleucel-T, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22336881

8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
Key words: blockade, checkpoints, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/22437870

9. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012 Apr 2. [Epub ahead of print]
Key words: predictive, genome, sequencing
http://www.ncbi.nlm.nih.gov/pubmed/22472521

10. Shamay M, Hand N, Lemas MV, Koon HB, Krown SE, Wrangle J, Desai P, Ramos JC, Ambinder RF. CpG methylation as a tool to characterize cell-free kaposi sarcoma herpesvirus DNA. J Infect Dis. 2012 Apr;205(7):1095-9. Epub 2012 Feb 22.
Key words: Kaposi, methylation, herpesvirus
http://www.ncbi.nlm.nih.gov/pubmed/22357696

11. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012 Apr;24(2):207-12. Epub 2012 Jan 9.
Key words: immunity, anti-tumor
http://www.ncbi.nlm.nih.gov/pubmed/22236695

12. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012 Mar 20;21(3):430-46.
Key words: demethylating, antitumor, hematological, epithelial
http://www.ncbi.nlm.nih.gov/pubmed/22439938

13. Vogelstein B, Kinzler KW. Winning the war: science parkour. Sci Transl Med. 2012 Mar 28;4(127):127ed2.
Key words: winning, war, parkour
http://www.ncbi.nlm.nih.gov/pubmed/22461636

14. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One. 2012;7(2):e31962.
Key words: trafficking, HER-2, depletion, regulatory, T Cells
http://www.ncbi.nlm.nih.gov/pubmed/22359647

15. Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate. 2012 Apr;72(5):487-98. doi: 10.1002/pros.21449.
Key words: lenalidomide, antibody, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/21748755

1. Drake CG, Antonarakis ES. Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol. 2012 Feb 9. [Epub ahead of print]
Key words: prostate cancer, treatment, immunological
http://www.ncbi.nlm.nih.gov/pubmed/22328018

2. Chen S, Principessa L, Isaacs JT. Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate. 2012 Mar 6. doi: 10.1002/pros.22503. [Epub ahead of print]
Key words: prostate cancer, prostaspheres, localized, isolated
http://www.ncbi.nlm.nih.gov/pubmed/22396312

3. Easwaran H, Baylin SB. Biomarkers for EGFR-antagonist response: In the genes, and on the genes! Clin Cancer Res. 2012 Feb 27. [Epub ahead of print]
Key words: EGFR, biomarker, antagonist
http://www.ncbi.nlm.nih.gov/pubmed/22371454

4. Easwaran H, Johnstone S, Vanneste L, Ohm J, Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D, Collisson E, Zhu JC, Yegnasubramanian S, Matsui W, Baylin SB. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 2012 Mar 5. [Epub ahead of print]
Key words: stem cell, hypermethylation, DNA
http://www.ncbi.nlm.nih.gov/pubmed/22391556

5. Ghiaur G, Gerber JM, Matsui W, Jones RJ. Cancer stem cells: relevance to clinical transplantation. Curr Opin Oncol. 2012 Mar;24(2):170-5.
Key words: transplantation, stem cell
http://www.ncbi.nlm.nih.gov/pubmed/22314617

6. Gladstone DE, Fuchs E. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Oncol. 2012 Mar;24(2):176-81.
Key words: hematopoietic, stem cell, leukemia
http://www.ncbi.nlm.nih.gov/pubmed/22234253

7. Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012 Mar 6. doi: 10.1002/pros.22504. [Epub ahead of print]
Key words: prostate cancer, BAT, androgen
http://www.ncbi.nlm.nih.gov/pubmed/22396319

8. Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2736-41. Epub 2011 Jun 20.
Key words: breast cancer, tamoxifen, HOXB7
http://www.ncbi.nlm.nih.gov/pubmed/21690342

9. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. A phase II study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 Feb 16. [Epub ahead of print]
Key words: rituximab, Hodgkin, lymphoma
http://www.ncbi.nlm.nih.gov/pubmed/22343727

10. Mullins JK, Loeb S. Environmental exposures and prostate cancer. Urol Oncol. 2012 Mar;30(2):216-9.
Key words: prostate cancer, environmental, exposure
http://www.ncbi.nlm.nih.gov/pubmed/22385992

11. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 2012 Feb 13;209(2):201-9. PubMed PMID: 22330682;
Key words: cancer, therapy, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/22330682

12. Rasheed ZA, Matsui W. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:15-8. doi: 10.1111/j.1440-1746.2011.07015.x.
Key words: pancreatic cancer, adenocarcinoma, stem cells
http://www.ncbi.nlm.nih.gov/pubmed/22320910

13. Shamay M, Hand N, Lemas MV, Koon HB, Krown SE, Wrangle J, Desai P, Ramos JC, Ambinder RF. CpG methylation as a tool to characterize cell-free kaposi sarcoma herpesvirus DNA. J Infect Dis. 2012 Apr;205(7):1095-9. Epub 2012 Feb 22.
Key words: Kaposi, sarcoma, herpesvirus, methulation
http://www.ncbi.nlm.nih.gov/pubmed/22357696

1. Armanios M, Price C. Telomeres and disease: An overview. Mutat Res. 2012 Feb 1;730(1-2):1-2.
Key words: telomere, disease
http://www.ncbi.nlm.nih.gov/pubmed/22100639

2. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res. 2012 Feb 1;730(1-2):52-8.
Key words: telomerase, pulmonary fibrosis
http://www.ncbi.nlm.nih.gov/pubmed/22079513

3. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):907-14.
Key words: breast cancer, cardiovascular disease, postmenopausal
http://www.ncbi.nlm.nih.gov/pubmed/22042368

4. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, Baylin SB. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res. 2012 Jan 25. [Epub ahead of print]
Key words: DNMT1, catalytic activity, enzymes
http://www.ncbi.nlm.nih.gov/pubmed/22278882

5. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012 Feb;69(2):415-24.
Key words: GTX, chemotherapy, pancreatic cancer
http://www.ncbi.nlm.nih.gov/pubmed/21800112

6. Fraser AV, Goodwin AC, Hacker-Prietz A, Sugar E, Woster PM, Casero RA Jr. Knockdown of ornithine decarboxylase antizyme 1 causes loss of uptake regulation leading to increased N (1), N (11)-bis(ethyl)norspermine (BENSpm) accumulation and toxicity in NCI H157 lung cancer cells. Amino Acids. 2012 Feb;42(2-3):529-38.
Key words: antizyme, lung cancer, ornithine
http://www.ncbi.nlm.nih.gov/pubmed/21814790

7. Gladstone DE, Blackford A, Cho E, Swinnen L, Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade J, Jones RJ. The Importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Jan 27. [Epub ahead of print]
Key words: leukemia, IGHV, lymphocytic
http://www.ncbi.nlm.nih.gov/pubmed/22285608

8. Hooker CM, Meguid RA, Hulbert A, Taylor JT, Shin J, Wrangle J, Rodgers K, Lee B, Laskshmanan S, Brown T, Meneshian A, Sussman M, Keruly J, Moore RD, Yang SC, Brock MV. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg. 2012 Feb;93(2):405-12.
Key words: lung cancer, immunodeficiency, infection
http://www.ncbi.nlm.nih.gov/pubmed/22269705

9. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):915-24. Epub 2011 Nov 11.
Key words: simvastatin, breast cancer, biomarker
http://www.ncbi.nlm.nih.gov/pubmed/22076478

10. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase i studies of safety and immune induction. Clin Cancer Res. 2012 Feb 1;18(3):858-868. Epub 2011 Dec 6.
Key words: listeria, mesothelin, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/22147941

11. Levis M. Phospho-specific Flow: Fixating on the target. Clin Cancer Res. 2012 Feb 2. [Epub ahead of print]
Key words: flow, phosphor-specific
http://www.ncbi.nlm.nih.gov/pubmed/22302900

12. Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti M, Huff CA, Borrello I. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012 Feb 2. [Epub ahead of print]
Key words: myeloma, vaccine, lenalidomide
http://www.ncbi.nlm.nih.gov/pubmed/22241792

13. Shabbeer S, Williams SA, Simons BW, Herman JG, Carducci MA. Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence. Cancer Prev Res (Phila). 2012 Feb;5(2):229-39. Epub 2011 Dec 2.
Key words: methyl donors, carcinogenesis, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/22139053

14. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids. 2012 Feb;42(2-3):887-98. Epub 2011 Jul 30.
Key words:demethylase, breast cancer, polyamine analogs
http://www.ncbi.nlm.nih.gov/pubmed/21805138

1. Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2011 Oct 22. [Epub ahead of print]
Key words: prostate cancer, anti-PSCA, monoclonal, antibody
http://www.ncbi.nlm.nih.gov/pubmed/22020316

2. Armstrong DK, Visvanathan K. The "luxury" of second malignancies. Gynecol Oncol. 2011 Dec;123(3):453-4. Epub 2011 Oct 11.
Key words: malignancies, second, luxury
http://www.ncbi.nlm.nih.gov/pubmed/21996261

3. Chen Y, Pullambhatla M, Byun Y, Foss CA, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate Cancer. Clin Cancer Res. 2011 Oct 31. [Epub ahead of print]
Key words: tanedioic, prostate cancer, PSMA
http://www.ncbi.nlm.nih.gov/pubmed/22042970

4. Gladstone DE, Swinnen L, Kasamon Y, Blackford A, Gocke CD, Griffin CA, Meade JB, Jones RJ. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Oct;52(10):1873-81. Epub 2011 Aug 18.
Key words: leukemia, immunoglobin, variable region
http://www.ncbi.nlm.nih.gov/pubmed/21851216

5. Hong S, Skaist AM, Wheelan SJ, Friedman AD. AP-1 protein induction during monopoiesis favors C/EBP: AP-1 heterodimers over C/EBP homodimerization and stimulates FosB transcription. J Leukoc Biol. 2011 Oct;90(4):643-51. Epub 2011 May 4.
Key words: AP-1, heterodimers, transcription, FosB
http://www.ncbi.nlm.nih.gov/pubmed/21543584

6. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res. 2011 Oct 15;17(20):6482-9. Epub 2011 Aug 10.
Key words: thyroid cancer, RAF, inhibitor
http://www.ncbi.nlm.nih.gov/pubmed/21831957

7. Jones1 S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2011 Oct 18. doi: 10.1002/humu.21633. [Epub ahead of print]
Key words: ARID1A, chromatin, somatic mutation
http://www.ncbi.nlm.nih.gov/pubmed/22009941

8. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE, Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garrett-Mayer E. Multi-institutional Phase II clinical and pharmacogenomics trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2011 Oct 14. [Epub ahead of print]
Key words: leukemia, tipifarnib, elderly
http://www.ncbi.nlm.nih.gov/pubmed/22001391

9. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. Epub 2011 Oct 10.
Key words: breast cancer, epithelial cell, BRCA1
http://www.ncbi.nlm.nih.gov/pubmed/21987798

10. Li R, Zhu J, Xie Z, Liao G, Liu J, Chen MR, Hu S, Woodard C, Lin J, Taverna SD, Desai P, Ambinder RF, Hayward GS, Qian J, Zhu H, Hayward SD. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe. 2011 Oct 4;10(4):390-400.
Key words: virus, DNA, dmagae, replication
http://www.ncbi.nlm.nih.gov/pubmed/22018239

11. Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res. 2011 Oct 12. [Epub ahead of print]
Key words: lung cancer, notch signaling, tumorigenesis
http://www.ncbi.nlm.nih.gov/pubmed/21994468

12. Sen T, Sen N, Huang Y, Sinha D, Luo ZG, Ratovitski E, Sidransky D. Tumor protein p63/nuclear factor kappa-B feedback loop in regulation of cell death. J Biol Chem. 2011 Oct 20. [Epub ahead of print]
Key words: feedback, kappa-B, cell death
http://www.ncbi.nlm.nih.gov/pubmed/22020940

13. Topalian SL, Weiner GJ, Pardoll DM. Cancer Immunotherapy Comes of Age. J Clin
Oncol. 2011 Oct 31. [Epub ahead of print]
Key words: cancer, immunotherapy, age
http://www.ncbi.nlm.nih.gov/pubmed/22042955

1. Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2011 Oct 22. [Epub ahead of print]
Key words: prostate cancer, anti-PSCA, monoclonal, antibody
http://www.ncbi.nlm.nih.gov/pubmed/22020316

2. Armstrong DK, Visvanathan K. The "luxury" of second malignancies. Gynecol Oncol. 2011 Dec;123(3):453-4. Epub 2011 Oct 11.
Key words: malignancies, second, luxury
http://www.ncbi.nlm.nih.gov/pubmed/21996261

3. Chen Y, Pullambhatla M, Byun Y, Foss CA, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate Cancer. Clin Cancer Res. 2011 Oct 31. [Epub ahead of print]
Key words: tanedioic, prostate cancer, PSMA
http://www.ncbi.nlm.nih.gov/pubmed/22042970

4. Gladstone DE, Swinnen L, Kasamon Y, Blackford A, Gocke CD, Griffin CA, Meade JB, Jones RJ. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Oct;52(10):1873-81. Epub 2011 Aug 18.
Key words: leukemia, immunoglobin, variable region
http://www.ncbi.nlm.nih.gov/pubmed/21851216

5. Hong S, Skaist AM, Wheelan SJ, Friedman AD. AP-1 protein induction during monopoiesis favors C/EBP: AP-1 heterodimers over C/EBP homodimerization and stimulates FosB transcription. J Leukoc Biol. 2011 Oct;90(4):643-51. Epub 2011 May 4.
Key words: AP-1, heterodimers, transcription, FosB
http://www.ncbi.nlm.nih.gov/pubmed/21543584

6. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res. 2011 Oct 15;17(20):6482-9. Epub 2011 Aug 10.
Key words: thyroid cancer, RAF, inhibitor
http://www.ncbi.nlm.nih.gov/pubmed/21831957

7. Jones1 S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2011 Oct 18. doi: 10.1002/humu.21633. [Epub ahead of print]
Key words: ARID1A, chromatin, somatic mutation
http://www.ncbi.nlm.nih.gov/pubmed/22009941

8. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE, Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garrett-Mayer E. Multi-institutional Phase II clinical and pharmacogenomics trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2011 Oct 14. [Epub ahead of print]
Key words: leukemia, tipifarnib, elderly
http://www.ncbi.nlm.nih.gov/pubmed/22001391

9. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. Epub 2011 Oct 10.
Key words: breast cancer, epithelial cell, BRCA1
http://www.ncbi.nlm.nih.gov/pubmed/21987798

10. Li R, Zhu J, Xie Z, Liao G, Liu J, Chen MR, Hu S, Woodard C, Lin J, Taverna SD, Desai P, Ambinder RF, Hayward GS, Qian J, Zhu H, Hayward SD. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe. 2011 Oct 4;10(4):390-400.
Key words: virus, DNA, dmagae, replication
http://www.ncbi.nlm.nih.gov/pubmed/22018239

11. Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res. 2011 Oct 12. [Epub ahead of print]
Key words: lung cancer, notch signaling, tumorigenesis
http://www.ncbi.nlm.nih.gov/pubmed/21994468

12. Sen T, Sen N, Huang Y, Sinha D, Luo ZG, Ratovitski E, Sidransky D. Tumor protein p63/nuclear factor kappa-B feedback loop in regulation of cell death. J Biol Chem. 2011 Oct 20. [Epub ahead of print]
Key words: feedback, kappa-B, cell death
http://www.ncbi.nlm.nih.gov/pubmed/22020940

13. Topalian SL, Weiner GJ, Pardoll DM. Cancer Immunotherapy Comes of Age. J Clin
Oncol. 2011 Oct 31. [Epub ahead of print]
Key words: cancer, immunotherapy, age
http://www.ncbi.nlm.nih.gov/pubmed/22042955

1. Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011 Sep 6. [Epub ahead of print]
Key words: lung cancer, angiogenesis
http://www.ncbi.nlm.nih.gov/pubmed/21896639

2. Antonarakis ES, Armstrong AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):206-18. doi: 10.1038/pcan.2011.24. Epub 2011 May 17.
Key words: prostate resistant, emerging, castration
http://www.ncbi.nlm.nih.gov/pubmed/21577233

3. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011 Sep;260(3):752-61. Epub 2011 Jul 19.
Key words: carcinoma, imaging, MR
http://www.ncbi.nlm.nih.gov/pubmed/21771960

4. Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol. 2011 Sep;35(9):1337-42.
Key words: urothelial, nests, papillary
http://www.ncbi.nlm.nih.gov/pubmed/21836490

5. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011 Sep 1;17(17):5793-800. Epub 2011 Jul 8.
Key words: pancreatic cancer, engrafment, gemcitabine
http://www.ncbi.nlm.nih.gov/pubmed/21742805

6. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2011 Sep 2. [Epub ahead of print]
Key words: cell compartments, hydroxymethylcytosine
http://www.ncbi.nlm.nih.gov/pubmed/21896958

7. Karafin M, Parwani AV, Netto GJ, Illei PB, Epstein JI, Ladanyi M, Argani P. Diffuse expression of PAX2 and PAX8 in the cystic epithelium of mixed epithelial stromal tumor, angiomyolipoma with epithelial cysts, and primary renal synovial sarcoma: evidence supporting renal tubular differentiation. Am J Surg Pathol. 2011 Sep;35(9):1264-73.
Key words: cysts, epithelial, sarcoma
http://www.ncbi.nlm.nih.gov/pubmed/21836481

8. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer. 2011 Sep;47(13):1955-61. Epub 2011 May 18.
Key words: angiotensin, carcinoma, renal
http://www.ncbi.nlm.nih.gov/pubmed/21600760

9. Lemmon CR, Woo JH, Tully E, Wilsbach K, Gabrielson E. Nuclear factor-{kappa}B (NF-{kappa}B) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase. J Biol Chem. 2011 Sep 9;286(36):31457-65. Epub 2011 Jul 16.
Key words: fatty, acid, inhibitors
http://www.ncbi.nlm.nih.gov/pubmed/21768098

10. Li L, Bailey E, Greenblatt S, Huso D, Small D. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knock-in mice. Blood. 2011 Sep 8. [Epub ahead of print]
Key words: agressiveness, myeloid, FLT3
http://www.ncbi.nlm.nih.gov/pubmed/21908433

11. Lotan T, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks J, Park B, Humphreys E, Partin A, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011 Aug 30. [Epub ahead of print]
Key words: prostate cancer, immunostaining
http://www.ncbi.nlm.nih.gov/pubmed/21878536

12. Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjær SK, Shih IeM, Roden RB. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011 Sep;122(3):560-6.
Key words: ovarian cancer, serologic
http://www.ncbi.nlm.nih.gov/pubmed/21704359

13. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers P, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila). 2011 Sep 1. [Epub ahead of print]
Key words: anastrozole, estrogen, postmenopause
http://www.ncbi.nlm.nih.gov/pubmed/21885816

14. Velculescu VE, Diaz LA Jr. Understanding the enemy. Sci Transl Med. 2011 Aug 31;3(98):98ps37.
Key words: understanding, enemy
http://www.ncbi.nlm.nih.gov/pubmed/21885403

15. Yovino S, Grossman SA. Treatment of glioblastoma in "elderly" patients. Curr Treat Options Oncol. 2011 Sep;12(3):253-62.
Key words: glioblastoma, elderly
http://www.ncbi.nlm.nih.gov/pubmed/21655911

Return to top of Publications - Oncology Archives


Search Publications
 
   
July 2014 articles:
Visit Animal Care and Use Committee Website
Current Classes
"Interinstitutional Assurance" Agreement (between Johns Hopkins and a company receiving an NIH research award)
Funding from Foundations/Private Sources
Request for Applications from the Chronic Effects of Neurotrauma Consortium (CENC)
5th Annual Michel Mirowski Discovery Award
Pancreatic Cancer Research Pilot Project Funding Available
The Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program
NEW! NIH Programs to Focus on Emerging Areas of Science

This Month's Departmental Listings

Upcoming Deadlines for August, September and October

       

 

JHM AppointmentsEmployment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM 

 

                                                                                                                                                           The Web Center